3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Breast
2
Tumor-Agnostic
1
Sarcoma
1
Other hematologic neoplasm
1
Other
1
Head & Neck
1
Genitourinary
1
Conditions
Testicular Germ Cell Tumor
1
Sarcoma
1
Ovarian Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
184
Magnetic Resonance Spectroscopy
162
Specimen Handling
134
enzalutamide
125
Nivolumab
118
Gemcitabine
96
Docetaxel
93
Radiosurgery
91
Prednisone
81
Androgen Antagonists
80
Abiraterone Acetate
79
Radiotherapy
75
apalutamide
66
Cisplatin
65
darolutamide
63
Ipilimumab
61
Biopsy
61
abiraterone
58
cabozantinib
55
Carboplatin
55
Leuprolide
52
enfortumab vedotin
51
Radiation
47
Pluvicto
45
Standard of Care
44
atezolizumab
41
Surveys and Questionnaires
38
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
37
X-Rays
37
olaparib
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hypnosis
×
Genitourinary
×
1 year
×
Clear all
NCT07614620
2026-05-29
HYPNO-AJA2
Institut Bergonié
Phase NA
Not yet recruiting
70 enrolled